Alaunos Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Alaunos is a clinical-stage oncology cell-therapy company developing non-viral TCR-T therapies. It has no product revenue and has recorded recurring losses since inception.
Financial performance and position
| Metric | Q1 2023 / March 31, 2023 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product revenue; no collaboration revenue reported | No collaboration revenue in Q1 2022 |
| Research and development expense | $6.5 million | $5.6 million in Q1 2022 |
| General and administrative expense | $3.2 million | $3.5 million in Q1 2022 |
| Net loss | $10.0 million; $0.04 per share | $9.8 million; $0.05 per share in Q1 2022 |
| Operating cash used | $9.4 million | $7.8 million in Q1 2022 |
| Cash, cash equivalents and restricted cash | $37.4 million, including $13.9 million restricted | $53.0 million at December 31, 2022 |
| Working capital | $7.2 million, excluding restricted cash | $15.7 million at December 31, 2022 |
| Total debt carrying value | $11.0 million | $16.8 million at December 31, 2022 |
| Total assets / liabilities | $48.6 million / $19.1 million | $64.9 million / $26.4 million at December 31, 2022 |
Margins are not meaningful because the company reported no revenue. The accumulated deficit was $890.7 million. Cash used in financing activities was $6.2 million, primarily reflecting $6.3 million of debt repayment, partly offset by $0.1 million from stock issuance.
Changes and notable events
- R&D expense rose 17% year over year, primarily due to increased TCR-T trial manufacturing and hunTR discovery work; lower employee costs partly offset the increase.
- G&A expense declined 10%, mainly from lower professional fees, insurance and facility costs.
- Interest expense increased to $0.9 million from $0.7 million; higher interest income helped reduce total other expense versus Q1 2022.
- After quarter-end, on May 1, 2023, the company repaid its SVB facility in full. The payment included $10.4 million of principal outstanding at March 31, accrued interest, a $1.4 million final payment and a $0.1 million prepayment premium.
- On April 3, 2023, the amended Precigen license retained Alaunos’s exclusive rights to TCR products targeting neoantigens or driver mutations, removed royalty and milestone obligations between the parties, and reduced the annual license fee to $75,000. IL-12 and CAR product rights are no longer licensed exclusively to Alaunos.
- On April 19, 2023, Alaunos terminated its Boston office lease; the filing reports a $0.2 million termination cost.
Outlook, risks and contingencies
- Management expected existing cash resources to fund operations into the fourth quarter of 2023, but stated that resources were not sufficient for at least one year after issuance of the financial statements. The filing therefore identifies substantial doubt about the company’s ability to continue as a going concern. No additional capital sources were committed.
- The company continued enrolling patients in its Phase 1/2 TCR-T Library trial across six solid-tumor indications. It anticipated treating 9–12 patients by year-end 2023, providing an interim update in Q3, and reaching Phase 2 readiness with a recommended dose by year-end; these are forward-looking targets, not assured outcomes.
- Management reported successful manufacture of multiple cryopreserved products during Q1 and continued process optimization. An IND filing for the mbIL-15 TCR-T program was anticipated in the second half of 2023; the company also aimed to add three TCRs to its library by year-end.
- Clinical evidence remains early and limited. The filing notes that the first two trial patients were removed following subsequent disease progression and cautions that interim or preliminary findings may not predict final results.
- Key risks include the need for financing, clinical and regulatory uncertainty, patient enrollment and manufacturing challenges, reliance on specialized suppliers and research partners, competition, and intellectual-property and licensing risks.
- Nasdaq had notified the company of a minimum-bid-price deficiency, with a stated compliance deadline of July 3, 2023. A reverse stock split was under consideration and required stockholder approval; delisting remained a risk.
Most important facts for investors to verify
- Cash runway and the actual effect of the May 1 debt repayment on available liquidity; the reported $37.4 million included restricted cash at quarter-end.
- Whether Alaunos obtains financing or a development partnership before its projected cash runway ends.
- Trial enrollment, safety and efficacy data, including whether the planned interim update and Phase 2-readiness target are achieved.
- Whether manufacturing changes and the mbIL-15 program progress on the timelines described.
- Nasdaq bid-price compliance and any decision or stockholder vote concerning a reverse split.